FVIII gene therapy (Poseida Therapeutics/Takeda)

N/A

Report date: 2025/01/26 18:49:47
NME

Base Information

Drug NameFVIII gene therapy (Poseida Therapeutics/Takeda)
Drug Alias Nameliver-directed non-viral gene therapy (Poseida Therapeutics/Takeda)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > OligonucleotideSmall molecules > Lipid
Mechanisms of ActionCoagulation factor VIII stimulants
TargetsCoagulation factor VIII
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPoseida Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPoseida Therapeutics Inc
Inactive CompaniesTakeda Pharmaceutical Co Ltd
Active IndicationsHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A